journal article·2024-10-01Open access

Recent advances in immunotherapy-involved combination cancer therapy based on ZIF-8

Guanheng Wang, Lin Li, Jiapeng Wang, Chang Liu, Chunlei Li, Xiuwen Zheng

AIP Advances· Volume 14· Issue 10

Abstract

This paper introduces and briefly describes the tumor immune cycle to clarify the action mechanisms and principles of classical immunotherapy. We then focus on the classification of immunotherapies. Immunotherapy strategies can be classified into three categories according to the target of action: immunotherapy based on the regulation of dendritic cells, immunotherapy based on polarized tumor-associated macrophages, and immunotherapy based on the suppression of regulatory T cells. Subsequently, the latest research progress in the use of Zeolitic Imidazolate Framework-8 (ZIF-8) as a vehicle to combine immunotherapy with other therapeutic approaches is examined. Finally, prospects for the application of nanocomposites in combination therapy for tumor immunotherapy are outlined.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Research and Treatments · Metal-Organic Frameworks: Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Medicine, Linyi University 1 , Linyi 276000,

Key Laboratory of Functional Nanomaterials and Technology in University of Shandong, Linyi University 2 , Linyi 276000,

Qilu Normal University 3 , Jinan 250013,

College of Chemistry and Chemical Engineering, Linyi University 4 , Linyi 276000,

Funding

National Natural Science Foundation of China · Linyi University

References (100+)

Show source-provided references
1. Ca-Cancer J. Clin. · 2022 · 72 · 710.3322/caac.21708 ↗
2. Eur. J. Cancer · 2009 · 45 · 74710.1016/j.ejca.2008.11.032 ↗
3. Eur. J. Cancer · 2009 · 45 · 75610.1016/j.ejca.2008.11.033 ↗
4. J. Natl. Cancer Center · 2024 · 4 · 4710.1016/j.jncc.2024.01.006 ↗
5. Adv. Sci. · 2023 · 10 · e220493210.1002/advs.202204932 ↗
6. Semin. Cancer Biol. · 2022 · 86 · 62410.1016/j.semcancer.2022.03.026 ↗
7. Curr. Med. Chem. · 2020 · 27 · 571610.2174/0929867326666190618161610 ↗
8. Nat. Rev. Clin. Oncol. · 2014 · 11 · 9110.1038/nrclinonc.2013.245 ↗
9. Bioorg. Chem. · 2019 · 85 · 32510.1016/j.bioorg.2019.01.019 ↗
10. Nat. Commun. · 2019 · 10 · 32410.1038/s41467-018-08165-y ↗
11. J. Nanobiotechnol. · 2019 · 17 · 710.1186/s12951-019-0445-7 ↗
12. Biomater. Sci. · 2019 · 7 · 108810.1039/c8bm00693h ↗
13. Gene · 2019 · 690 · 13710.1016/j.gene.2019.01.002 ↗
14. Small · 2019 · 15 · e180411110.1002/smll.201804111 ↗
15. Small · 2019 · 15 · e180467110.1002/smll.201804671 ↗
16. Adv. Mater. · 2019 · 31 · e180609510.1002/adma.201806095 ↗
17. Acta Pharmacol. Sin. · 2020 · 41 · 97010.1038/s41401-020-0424-4 ↗
18. Acta Pharmacol. Sin. · 2020 · 41 · 89510.1038/s41401-020-0423-5 ↗
19. Expert Opin. Drug Delivery · 2019 · 16 · 109510.1080/17425247.2019.1662786 ↗
20. Pharmaceuticals · 2019 · 12 · 16310.3390/ph12040163 ↗
21. Expert Opin. Drug Metab. Toxicol. · 2021 · 17 · 32310.1080/17425255.2021.1862085 ↗
22. Adv. Mater. · 2019 · 31 · e190159210.1002/adma.201970192 ↗
23. RSC Adv. · 2020 · 10 · 3760010.1039/d0ra07950b ↗
24. J. Am. Chem. Soc. · 2016 · 138 · 96210.1021/jacs.5b11720 ↗
25. Drug Delivery Transl. Res. · 2023 · 13 · 193610.1007/s13346-022-01241-3 ↗
26. Nanoscale · 2019 · 11 · 2103010.1039/c9nr06558j ↗
27. Nat. Rev. Immunol. · 2020 · 20 · 32110.1038/s41577-019-0269-6 ↗
28. Eur. J. Pharmacol. · 2009 · 625 · 4110.1016/j.ejphar.2009.09.067 ↗
29. Breast Cancer: Targets Ther. · 2019 · 11 · 5310.2147/bctt.s175360 ↗
30. Acta Haematol. · 2019 · 141 · 10710.1159/000495558 ↗
31. Adv. Mater. · 2021 · 33 · e200763010.1002/adma.202170259 ↗
32. Arch. Iran. Med. · 2009 · 12 · 395
33. Front. Immunol. · 2013 · 4 · 49010.3389/fimmu.2013.00490 ↗
34. Adv. Mater. · 2022 · 34 · e220105410.1002/adma.202201054 ↗
35. Biomaterials · 2017 · 148 · 1610.1016/j.biomaterials.2017.09.017 ↗
36. Immunity · 2013 · 39 · 110.1016/j.immuni.2013.07.012 ↗
37. Annu. Rev. Med. · 2018 · 69 · 30110.1146/annurev-med-012017-043208 ↗
38. Nat. Rev. Immunol. · 2022 · 22 · 20910.1038/s41577-021-00574-3 ↗
39. Hum. Vaccines Immunother. · 2016 · 12 · 186310.1080/21645515.2016.1147635 ↗
40. Theranostics · 2021 · 11 · 747110.7150/thno.59953 ↗
41. Cell · 2011 · 147 · 135510.1016/j.cell.2011.11.021 ↗
42. Annu. Rev. Immunol. · 2010 · 28 · 44510.1146/annurev-immunol-030409-101212 ↗
43. Nat. Immunol. · 2015 · 16 · 72910.1038/ni.3196 ↗
44. Ther. Adv. Med. Oncol. · 2022 · 14 · 1758835922109621910.1177/17588359221096219 ↗
45. Pharmacol. Rev. · 2015 · 67 · 73110.1124/pr.114.009456 ↗
46. Int. J. Mol. Sci. · 2022 · 23 · 435210.3390/ijms23084352 ↗
47. Nat. Rev. Immunol. · 2017 · 17 · 3010.1038/nri.2016.116 ↗
48. Front. Immunol. · 2013 · 4 · 43810.3389/fimmu.2013.00438 ↗
49. Immunity · 2023 · 56 · 221810.1016/j.immuni.2023.08.014 ↗
50. Am. J. Cancer Res. · 2021 · 11 · 3777
51. Clin. Cancer Res. · 1999 · 5 · 2963
52. Eur. J. Immunol. · 2012 · 42 · 122610.1002/eji.201142053 ↗
53. Cancer Immunol. Immunother. · 2016 · 65 · 115910.1007/s00262-016-1879-5 ↗
54. Sci. Rep. · 2018 · 8 · 350010.1038/s41598-018-21891-z ↗
55. J. Clin. Invest. · 2023 · 133 · e16344910.1172/jci163449 ↗
56. J. Autoimmun. · 2015 · 63 · 110.1016/j.jaut.2015.07.011 ↗
57. Clin. Cancer Res. · 2017 · 23 · 324110.1158/1078-0432.ccr-16-3122 ↗
58. Nanoscale · 2021 · 13 · 470510.1039/d0nr08050k ↗
59. Semin. Cancer Biol. · 2021 · 69 · 23810.1016/j.semcancer.2019.11.010 ↗
60. Acta Pharm. Sin. B · 2020 · 10 · 211010.1016/j.apsb.2020.05.008 ↗
61. J. Leukocyte Biol. · 2009 · 86 · 106510.1189/jlb.0609385 ↗
62. Neuro-Oncology · 2017 · 19 · 143510.1093/neuonc/nox081 ↗
63. J. Immunol. · 2007 · 178 · 288310.4049/jimmunol.178.5.2883 ↗
64. Immunology · 2006 · 117 · 43310.1111/j.1365-2567.2006.02321.x ↗
65. Mucosal Immunol. · 2010 · 3 · 23010.1038/mi.2010.7 ↗
66. Growth Factors · 2015 · 33 · 9210.3109/08977194.2015.1010645 ↗
67. Curr. Top. Microbiol. Immunol. · 2011 · 350 · 12710.1007/82_2010_87 ↗
68. Nat. Rev. Immunol. · 2005 · 5 · 64110.1038/nri1668 ↗
69. J. Clin. Invest. · 2006 · 116 · 277710.1172/jci28828 ↗
70. Immunol. Rev. · 2008 · 222 · 18010.1111/j.1600-065x.2008.00608.x ↗
71. Semin. Cancer Biol. · 2017 · 43 · 7410.1016/j.semcancer.2017.03.001 ↗
72. Nat. Immunol. · 2018 · 19 · 131910.1038/s41590-018-0226-8 ↗
73. Science · 2009 · 324 · 102910.1126/science.1160809 ↗
74. Front. Immunol. · 2018 · 9 · 159110.3389/fimmu.2018.01591 ↗
75. Cancer Res. · 2014 · 74 · 2410.1158/0008-5472.can-13-1196 ↗
76. Cancer Res. · 2010 · 70 · 572810.1158/0008-5472.can-09-4672 ↗
77. Oncotarget · 2014 · 5 · 966410.18632/oncotarget.1856 ↗
78. Trends Cancer · 2022 · 8 · 94410.1016/j.trecan.2022.06.008 ↗
79. Semin. Immunol. · 2021 · 52 · 10147610.1016/j.smim.2021.101476 ↗
80. J. Immunother. Cancer · 2021 · 9 · e00259110.1136/jitc-2021-002591 ↗
81. ESMO Open · 2023 · 8 · 10078410.1016/j.esmoop.2023.100784 ↗
82. Eur. J. Cancer · 2016 · 52 · 5010.1016/j.ejca.2015.08.021 ↗
83. Trends Cancer · 2017 · 3 · 58310.1016/j.trecan.2017.06.005 ↗
84. Sci. China Life Sci. · 2019 · 62 · 17910.1007/s11427-018-9428-9 ↗
85. Nat. Rev. Cancer · 2008 · 8 · 29910.1038/nrc2355 ↗
86. Theranostics · 2023 · 13 · 29510.7150/thno.80687 ↗
87. Acta Pharmacol. Sin. · 2023 · 44 · 28810.1038/s41401-022-00953-z ↗
88. Small · 2023 · 19 · e220621110.1002/smll.202206211 ↗
89. Heliyon · 2022 · 8 · e0957710.1016/j.heliyon.2022.e09577 ↗
90. Nat. Rev. Clin. Oncol. · 2018 · 15 · 20510.1038/nrclinonc.2017.194 ↗
91. Eur. Arch. Otorhinolaryngol. · 2016 · 273 · 134710.1007/s00405-015-3553-5 ↗
92. Adv. Mater. · 2019 · 31 · e190415610.1002/adma.201904156 ↗
93. ACS Appl. Mater. Interfaces · 2019 · 11 · 3263310.1021/acsami.9b09568 ↗
94. Cell · 2017 · 168 · 48710.1016/j.cell.2016.12.022 ↗
95. Science · 2015 · 348 · 5610.1126/science.aaa8172 ↗
96. Nat. Rev. Cancer · 2012 · 12 · 25210.1038/nrc3239 ↗
97. BMC Med. · 2016 · 14 · 7310.1186/s12916-016-0623-5 ↗
98. J. Clin. Invest. · 2014 · 124 · 68710.1172/jci67313 ↗
99. Cell · 2017 · 170 · 105510.1016/j.cell.2017.08.031 ↗
100. Nat. Rev. Drug Discovery · 2019 · 18 · 19710.1038/s41573-018-0007-y ↗